Digital Sponsored Antiviral development in the age of AI: From pre-IND to earl... hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.
Oncology On the benefits of earlier oncological intervention, with Jo... As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia
Oncology On GDF-15 neutralisation and cachexia, with CatalYm As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.
R&D Sponsored Beyond recruitment: Creating patient engagement that lasts In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.
R&D Taking the microbiome seriously, with Sam Possemiers pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.
Oncology Dr Michael Bauer on Quantro’s mission to drug the “undruggab... Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.